Neuroprotection from the collateral perspective

IDrugs

Volumn 8, Issue 3, 2005, Pages 222-228

  Liebeskind, David S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiography; Collateral circulation; Collaterals; Imaging; Leptomeningeal; Neuprotection; Stroke

Indexed keywords

ALBUMIN; ARUNDIC ACID; AX 200; CAFFEINOL; CALCIUM CHANNEL BLOCKING AGENT; DIAZEPAM; DISUFENTON SODIUM; GLYCERYL TRINITRATE; GRANULOCYTE COLONY STIMULATING FACTOR; MAGNESIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; PARACETAMOL; PICLOZOTAN; TISSUE PLASMINOGEN ACTIVATOR; TS 011; UNCLASSIFIED DRUG; VASCULOTROPIN; VASOACTIVE AGENT;

BRAIN PERFUSION; CARDIOVASCULAR SYSTEM; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLLATERAL CIRCULATION; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; HEMODYNAMICS; HUMAN; IMAGING SYSTEM; INDUCED HYPOTHERMIA; MEDICAL RESEARCH; NEUROPROTECTION; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; REVASCULARIZATION; REVIEW;

ANIMALS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS, PHASE III; COLLATERAL CIRCULATION; HUMANS; NEUROPROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 17044395566     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Nilasena DS, Kresowik TF, Wiblin RT, Piskac AF, Kresowik RA, Brenton MA, Wilwert JM, Hendel ME: Assessing patterns of tPA use in acute stroke. Stroke (2002) 33:Abs 354.
2. Kidwell CS, Liebeskind DS, Starkman S, Saver JL: Trends in acute ischemic stroke trials through the 20th century. Stroke (2001) 32(6):1349-1359.
3. De Keyser J, Sulter G, Luiten PG: Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing? Trends Neurosci (1999) 22(12):535-540.
4. DeGraba TJ, Pettigrew LC: Why do neuroprotective drugs work in animals but not humans? Neurol Clin (2000) 18 2):475-493.
5. Hoyte L, Kaur J, Buchan AM: Lost in translation: Taking neuroprotection from animal models to clinical trials. Exp Neurol (2004) 188(2):200-204.
6. Gladstone DJ, Black SE, Hakim AM: Toward wisdom from failure: Lessons from neuroprotective stroke trials and new therapeutic directions. Stroke (2002) 33(8):2123-2136.
7. Grotta J: Why do all drugs work in animals but none in stroke patients? 2. Neuroprotective therapy. J Intern Med (1995) 237(1):89-94.
8. Liebeskind DS, Kasner SE: Neuroprotection for ischaemic stroke: An unattainable goal? CNS Drugs (2001) 15 3):165-174.
9. Ovbiagele B, Kidwell CS, Starkman S, Saver JL: Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke. Curr Treat Options Neurol (2003) 5 5):367-375.
10. Wahlgren NG, Ahmed N: Neuroprotection in cerebral ischaemia: Facts and fancies - the need for new approaches. Cerebrovasc Dis (2004) 17(Suppl 1):153-166.
11. Stroke Therapy Academic Industry Roundtable: Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke (1999) 30:2752-2758.
12. Stroke Therapy Academic Industry Roundtable II: Recommendations for clinical trial evaluation of acute stroke therapies. Stroke (2001) 32:1598-1606.
13. Fisher M: Recommendations for advancing development of acute stroke therapies: Stroke therapy academic industry roundtable 3. Stroke (2003) 34(6):1539-1546.
14. Neuroprotection - drugs, markets and companies: Jain PharmaBiotech, Basel, Switzerland (2004). http://www.researchandmarkets.com/reportinfo.asp?report_id=39073
15. Gerriets T, Stolz E, Walberer M, Muller C, Rottger C, Kluge A, Kaps M, Fisher M, Bachmann G: Complications and pitfalls in rat stroke models for middle cerebral artery occlusion: A comparison between the suture and the macrosphere model using magnetic resonance angiography. Stroke (2004) 35(10):2372-2377.
16. No authors listed: Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological disorders and stroke rtPA stroke study group. N Engl J Med (1995) 333 24):1581-1587.
17. Liebeskind DS: Collateral circulation. Stroke (2003) 34(9):2279-2284.
18. Liebeskind DS: Collateral therapeutics for cerebral ischemia. Expert Rev Neurotherapeutics (2004) 4 2):255-265.
19. Selco SL, Liebeskind DS: Hyperacute imaging of ischemic stroke: Role in therapeutic management. Curr Cardiol Rep (2005) 7(1):10-15.
20. Gordon DL, Bendixen BH, Adams HP Jr, Clarke W, Kappelle LJ, Woolson RF: Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke: Implications for clinical trials. The TOAST investigators. Neurology (1993) 43(5):1021-1027.
21. Liebeskind DS, Ances BM, Weigele JB, Hurst RW: Intravascular deoxygenation of leptomeningeal collaterals detected with gradient-echo MRI. Stroke (2004) 35:Abs 266.
22. Traystman RJ: Animal models of focal and global cerebral ischemia. ILAR J (2003) 44(2):85-95.
23. Fukuda S, del Zoppo GJ: Models of focal cerebral ischemia in the nonhuman primate. ILAR J (2003) 44(2):96-104.
24. Oliff HS, Coyle P, Weber E: Rat strain and vendor differences in collateral anastomoses. J Cereb Blood Flow Metab (1997) 17(5):571-576.
25. Calamante F, Gadian DG, Connelly A: Delay and dispersion effects in dynamic susceptibility contrast MRI: Simulations using singular value decomposition. Magn Reson Med (2000) 44 3):466-473.
26. Warach S: Use of diffusion and perfusion magnetic resonance imaging as a tool in acute stroke clinical trials. Curr Control Trials Cardiovasc Med (2001) 2(1):38-44.
27. Grotta J: Combination therapy stroke trial: Recombinant tissue-type plasminogen activator with/without lubeluzole. Cerebrovasc Dis (2001) 12(3):258-263.
28. Lyden P, Jacoby M, Schim J, Albers G, Mazzeo P, Ashwood T, Nordlund A, Odergren T: The clomethiazole acute stroke study in tissue-type plasminogen activator-treated stroke (CLASS-T): Final results. Neurology (2001) 57(7):1199-1205.
29. No authors listed: Major ongoing stroke trials. Stroke (2004) 35(10):Abs e359-e368.
30. Weir CJ, Kaste M, Lees KR: Targeting neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy. Stroke (2004) 35(9):2111-2116.
31. Wang Y, Kilic E, Kilic U, Weber B, Bassetti CL, Marti HH, Hermann DM: VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain (2005) 128(Pt 1):52-63.